Oncology And Cancer Research

Cipla has licensed Sino Biopharm's HER2 biparatopic ADC TQB2102 for India, South Africa and five other emerging markets. The deal caps at USD 123 million plus double-digit royalties, with access to HER2-low breast cancer as the core case. #SyenzaNews #Oncology #MarketAccess #DrugDevelopment

Insurers are spending billions on breakthrough medicines, but the tests that decide who gets them are still an afterthought. Kathryn Phillips lays out four reforms to link drug and diagnostic policy pathways. #SyenzaNews #diagnostics #healtheconomics #MarketAccess

The European Commission has approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making Trodelvy the first ADC-based backbone across PD-L1 status.

Merck and Moderna's individualized neoantigen therapy intismeran has cleared its first Phase 3, beating KEYTRUDA alone in resected high-risk melanoma. The open question now is how payers value a medicine made for one patient at a time.

How can blended capital unlock breakthroughs in pediatric cancer treatments? Developing drugs for childhood cancers faces unique challenges—small patient populations, high risks, and limited commercial returns often deter traditional investors. This article examines why combining public grants, venture funding, and philanthropic support is critical to advancing therapies in oncology. Read the full analysis to explore innovative financing models driving progress. #SyenzaNews #oncology #biotechnology #innovation #HealthEconomics

How are cell therapies redefining cancer care through rigorous HTA evaluation? INCA’s latest analysis highlights how CAR-T and other advanced cell therapies are shifting oncology paradigms—balancing innovation with evidence-based access and cost-effectiveness. Explore the full breakdown and its implications for global cancer treatment. #SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

💰 Is pembrolizumab delivering high value for HNSCC in Switzerland? A new analysis confirms the immunotherapy offers strong cost-effectiveness, supporting smarter resource allocation and improved patient outcomes in oncology. Explore the full economic evaluation and its implications for market access. #SyenzaNews #oncology #HealthEconomics #costeffectiveness #MarketAccess

Is the PRIME scheme growing more exclusive for innovative medicines? Eligibility criteria for the European Medicines Agency’s PRIME scheme remain highly selective in 2026, underscoring the rigorous standards required to secure early regulatory support for therapies addressing unmet medical needs. Discover what this means for drug developers and patients. #SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #MarketAccess

Portugal's INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.

How is Portugal expanding access to advanced prostate cancer therapies? The country has approved reimbursement for the niraparib-abiraterone combination, strengthening patient options in oncology and highlighting progress in pharmaceutical market access. Discover what this means for treatment innovation and healthcare policy. #SyenzaNews #oncology #MarketAccess

GSK's Q2 2026 pipeline acceleration is driving strong earnings growth! Core profits up 7%, EPS +9% fueled by specialty medicines and vaccines. Check out the insights: #GSK #Pipeline #Pharma

How could dual-targeting therapies reshape outcomes for patients with relapsed myeloma? A new clinical trial has delivered major progression-free survival gains by simultaneously hitting two key targets, offering fresh hope in a hard-to-treat setting. Explore the trial results and what they mean for future treatment strategies. #SyenzaNews #oncology #clinicaltrials #innovation